Phaseline

Companies › Nuvation Bio

Nuvation Bio: clinical trials, targets and expected readouts

3 active drug programs in 7 registered trials: 3 Phase 3, 3 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Taletrectinib
Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor
ROS1, NTRK1, NTRK2, NTRK3Phase 3Non Small Cell Lung Cancer; Non-small Cell Lung Cancer (NSCLC)Jun 2027
Safusidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 3Glioma; Grade 2 IDH1-mutant GliomaDec 2028
NUV-1511–Phase 1Advanced Solid TumorMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06334432NUV-1511Phase 1Advanced Solid TumorOncologyMar 2027
NCT04395677TaletrectinibPhase 2Non Small Cell Lung CancerOncologyJun 2027
NCT04919811TaletrectinibPhase 2Non Small Cell Lung CancerOncologyDec 2027
NCT05303519SafusidenibPhase 3GliomaOncologyDec 2028
NCT06564324TaletrectinibPhase 3Non Small Cell Lung CancerOncologyJan 2029
NCT07154706TaletrectinibPhase 3Non-small Cell Lung Cancer (NSCLC)OncologyAug 2030
NCT07703436SafusidenibPhase 2Grade 2 IDH1-mutant GliomaOncologySep 2030

From the company's SEC filings

Cash and short-term investments of $663m on 2026-09-30; operating cash outflow about $103m a year; runway about 78 months at that burn, to Mar 2033; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ROS1 (1) NTRK1 (1) NTRK2 (1) NTRK3 (1) IDH1 (1)

Companies with the same targets

Bristol-Myers Squibb Xuanzhu Biopharmaceutical Roche Turning Point Therapeutics Dompé Farmaceutici Teligene US Bayer Servier IDEAYA Biosciences Ascentage Pharma Group

Companies built like this

Xuanzhu Biopharmaceutical Hutchmed Servier Corvus Pharmaceuticals Avistone Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.